LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on developing and commercializing innovative products for respiratory, inflammatory and critical care diseases, today reported financial results for the quarter ended June 30, 2007. During the second quarter of 2007, the U.S. Food and Drug Administration (FDA) approved twice-daily ZYFLO CRTM (zileuton) extended-release tablets for the prevention and chronic treatment of asthma.
